Predictors of treatment response to pregabalin in unexplained or refractory chronic cough - 31/10/23
Abstract |
Background |
Patients with chronic cough (>8 weeks) often remain symptomatic after appropriate investigations and therapeutic trials. Prior research has shown a benefit in certain individuals from pregabalin, but clinical improvement is quite unpredictable and variable.
Objective |
The main objective of this study was to identify the demographic and clinical characteristics associated with a higher likelihood of cough improvement with a trial of pregabalin therapy.
Methods |
50 consecutive patients with chronic cough were enrolled in this prospective cohort study. Subjects were prescribed pregabalin 75 mg oral qhs for 4 weeks followed by 75 mg oral bid. Leicester Cough Questionnaire (LCQ) was completed at treatment initiation and after 3 months of therapy. A comparison was performed between treatment responders (LCQ total score improvement ≥1.3) and non-responders.
Results |
56% of patients reported a LCQ total score improvement ≥1.3 (minimal clinically important difference). Responders to pregabalin therapy were more likely to have refractory (with underlying pulmonary disease) versus unexplained chronic cough (p = 0.01). Patients with significant improvement were also on average more symptomatic at baseline (mean LCQ total score 10.2 versus 13.0, p < 0.01). No significant relationship was identified with age, gender, body mass index, history of anxiety and/or depression, cigarette smoking history, or cough duration (p > 0.05). The unexplained chronic cough group had a strong female predominance (85.7% versus 40.9% for refractory cough, p < 0.01).
Conclusion |
This is the first study that has investigated clinical predictors of treatment response to pregabalin in chronic cough patients. Further research is needed to develop therapies for subjects who do not improve with currently available neuromodulating medications.
Le texte complet de cet article est disponible en PDF.Highlights |
• | 1–56% of chronic cough patients reported a significant LCQ total score improvement. |
• | Responders were more likely to have refractory versus unexplained chronic cough. |
• | Patients with clinical improvement were on average more symptomatic at baseline. |
• | A strong female predominance was seen in patients with unexplained chronic cough. |
Keywords : Cough, Chronic cough, Pregabalin, Treatment response
Plan
| ☆ | 50 consecutive patients (January 2019 to October 2022) with unexplained or refractory chronic cough were enrolled in this prospective cohort study at Montfort Hospital (Ottawa, Ontario, Canada). The project received Montfort Hospital research ethics board approval (file #22-23-07-018). All subjects had been assessed by a pulmonologist and had completed extensive investigations including pulmonary function testing and chest computed tomography. Patients were initiated on pregabalin at a dose of 75 mg oral qhs for 4 weeks followed by 75 mg oral bid. Speech therapy was not permitted during the study period. |
| ☆☆ | Subjects completed the Leicester Cough Questionnaire (LCQ) at treatment initiation and after 3 months of therapy to measure cough-related quality of life [11]. Patients were considered to have responded to pregabalin therapy if the LCQ total score improved by ≥ 1.3 (minimal clinically important difference) [12]. Results were also charted for all 3 LCQ domains: physical, psychological, and social. |
Vol 218
Article 107396- novembre 2023 Retour au numéro
Article précédent
- Minimal effective dose of maintenance steroid therapy for relapse of cryptogenic organizing pneumonia
- Kenichiro Atsumi, Kakeru Hisakane, Erika Mikami, Takahiro Suzuki, Satoru Matsuki, Masahiro Seike, Takashi Hirose
- EUFOREA pocket guide on the diagnosis and management of asthma: An educational and practical tool for general practitioners, non-respiratory physicians, paramedics and patients
- Zuzana Diamant, Milos Jesenak, Nicola A. Hanania, Liam G. Heaney, Ratko Djukanovic, Dermot Ryan, Santiago Quirce, Vibeke Backer, Mina Gaga, Ian Pavord, Darío Antolín-Amérigo, Sara Assaf, Petros Bakakos, Anna Bobcakova, William Busse, Jasper Kappen, Stelios Loukides, Maurits van Maaren, Petr Panzner, Helena Pite, Antonio Spanevello, Henning Stenberg, Ilja Striz, Boony Thio, Martina Koziar Vasakova, Diego Conti, Wytske Fokkens, Susanne Lau, Glenis K. Scadding, Elizabeth Van Staeyen, Peter W. Hellings, Leif Bjermer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?